Results 201 to 210 of about 40,241 (253)

Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. [PDF]

Psoriasis (Auckl)
Gisondi P, Bellinato F, Curic T, Girolomoni G.   +3 more
europepmc   +1 more source

Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching. [PDF]

JAAD Int
Aghajani M, Pham J, Sholji T, Burrell K, Kok C, Frew JW.   +5 more
europepmc   +1 more source

Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry. [PDF]

Gastro Hep Adv
Oketola B, Bernatsky S, Lukusa L, Moura CS, Neville A, Leung Y, Narula N, Afif W, Birck MG, Zezos P, Singh H, Canadian IBD Research Consortium.   +11 more
europepmc   +1 more source

Law & Health Care Newsletter, Summer 2018 [PDF]

, 2018

core   +1 more source

Anti-vascular endothelial growth factor (anti-VEGF) agents for neovascular age-related macular degeneration (nAMD): a network meta-analysis. [PDF]

Cochrane Database Syst Rev
Lucenteforte E, Ng SM, Saulle R, Hoad G, Schillinger R, Virgili G.   +5 more
europepmc   +1 more source

Biosimilar insulins: Informed choice for South Asia

, 2015
Sanjay Kalra, A K Azad Khan, Syed Abbas Raza, Noel Somasundaram, Dina Shrestha, Zafar Ahmed Latif, Sarita Bajaj, Md Faruque Pathan, Rakesh Sahay, Hajera Mahtab   +9 more
openalex   +1 more source

Will the emerging private-label market access channel help or hinder biosimilar market access? [PDF]

J Manag Care Spec Pharm
Mehr SR.
europepmc   +1 more source

Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

JAMA Netw Open
Riegler JS, Kesselheim AS, Rome BN.
europepmc   +1 more source

Clinical and Real-World Evidence on Etanercept Biosimilar Switching: A Narrative Literature Review of Efficacy and Safety. [PDF]

Adv Ther
Schmalzing M, Askari A, Girolomoni G, Perez-Coleman JCV, Salvati C, Bachinskaya E.   +5 more
europepmc   +1 more source

Response to Infliximab Biosimilar in a Case of Reactive Arthritis: Our Experience

, 2019
A Morey, Bhushan Madke, Adarshlata Singh, Sudhir Singh, Sandeep Kulkarni   +4 more
openalex   +1 more source